Differential Regulation of the Melanoma Proteome by eIF4A1 and eIF4E.
Accepted version
Peer-reviewed
Repository URI
Repository DOI
Change log
Authors
Abstract
Small molecules and antisense oligonucleotides that inhibit the translation initiation factors eIF4A1 and eIF4E have been explored as broad-based therapeutic agents for cancer treatment, based on the frequent upregulation of these two subunits of the eIF4F cap-binding complex in many cancer cells. Here, we provide support for these therapeutic approaches with mechanistic studies of eIF4F-driven tumor progression in a preclinical model of melanoma. Silencing eIF4A1 or eIF4E decreases melanoma proliferation and invasion. There were common effects on the level of cell-cycle proteins that could explain the antiproliferative effects in vitro Using clinical specimens, we correlate the common cell-cycle targets of eIF4A1 and eIF4E with patient survival. Finally, comparative proteomic and transcriptomic analyses reveal extensive mechanistic divergence in response to eIF4A1 or eIF4E silencing. Current models indicate that eIF4A1 and eIF4E function together through the 5'UTR to increase translation of oncogenes. In contrast, our data demonstrate that the common effects of eIF4A1 and eIF4E on translation are mediated by the coding region and 3'UTR. Moreover, their divergent effects occur through the 5'UTR. Overall, our work shows that it will be important to evaluate subunit-specific inhibitors of eIF4F in different disease contexts to fully understand their anticancer actions. Cancer Res; 77(3); 613-22. ©2016 AACR.
Description
Keywords
Journal Title
Conference Name
Journal ISSN
1538-7445
Volume Title
Publisher
Publisher DOI
Rights
Sponsorship
European Research Council (242664)
Medical Research Council (MR/L00156X/1)
Cancer Research UK (CB4220)
Breast Cancer Now (None)
European Molecular Biology Organization (EMBO) (2045)
Urology Foundation (ADAM NELSON SCHOL 2013/2014)
Louis-Jeantet Foundation (YICA2014)
European Research Council (646876)
Society for Endocrinology (SEMINAR)
Urology Foundation (unknown)
Anticancer Fund (ACF) (unknown)
Susan G Komen Breast Cancer Foundation (SAC160065)